CORV - CORV -1.5% on FDA complete response letter December, 24 2019 08:17 AM Correvio Pharma Corp. Correvio Pharma (NASDAQ:CORV) receives a complete response letter saying that the FDA can't approve the NDA for Brinavess in its present form.More news on: Correvio Pharma Corp., Healthcare stocks news, Stocks on the move, Read more ...